Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 9:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 2,670 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo oral capsule Clear all
Not listed Phase 1 Interventional Accepts healthy volunteers

28-Day Repeat-Dose, Dose Escalation Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men

NCT03298373
View directory record Official record
Conditions
Healthy Men, Male Contraception
Interventions
Placebo, 11β-methyl-nortestosterone-dodecylcarbonate
Drug
Lead sponsor
Premier Research
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Oct 8, 2026, 9:36 PM EDT
Recruiting Phase 2 Interventional

Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking

NCT07214207
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Suvorexant 10 mg, Placebo
Drug · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 8, 2026, 9:36 PM EDT
Completed Phase 2 Interventional

Safety of Pioglitazone for Hematoma Resolution In Intracerebral Hemorrhage

NCT00827892
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Pioglitazone, Placebo Control
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 8, 2026, 9:36 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

NCT05619692
View directory record Official record
Conditions
Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
Interventions
SAGE-718, SAGE-718-matching Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
37
States / cities
Gilbert, Arizona • Phoenix, Arizona • Lafayette, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 8, 2026, 9:36 PM EDT
Completed Not applicable Interventional

Vitamin D Administration in the Nursing Home

NCT00204919
View directory record Official record
Conditions
Vitamin D Deficiency, Osteoporosis
Interventions
Vitamin D, placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
55 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 8, 2026, 9:36 PM EDT
Active, not recruiting Phase 3 Interventional

Psilocybin for Major Depressive Disorder (MDD)

NCT06308653
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Psilocybin 25 mg, Inactive Placebo, Psilocybin 5 mg, Psychosocial Support
Drug · Behavioral
Lead sponsor
Usona Institute
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
29
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 8, 2026, 9:36 PM EDT
Completed Phase 3 Interventional Results available

Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)

NCT01938001
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Rituximab, Lenalidomide, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
35
States / cities
Mobile, Alabama • Glendale, Arizona • Escondido, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 8, 2026, 9:36 PM EDT
Terminated Phase 2 Interventional

Cariprazine Effects on Brain and Behavior in Cocaine Use Disorder

NCT03430544
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Cariprazine Oral Capsule [Vraylar], Placebo oral capsule
Drug
Lead sponsor
Anna Rose Childress, Ph.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 8, 2026, 9:36 PM EDT
Completed Phase 2 Interventional Results available

A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)

NCT02139943
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
25 Years to 65 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
46
States / cities
Little Rock, Arkansas • Concord, California • La Jolla, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Oct 8, 2026, 9:36 PM EDT
Completed Phase 3 Interventional Results available

Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA

NCT00852540
View directory record Official record
Conditions
Skin Infections, Bacterial
Interventions
Retpamulin Ointment, 1%, Linezolid
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
2 Months and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
53
States / cities
Anniston, Alabama • Birmingham, Alabama • Bentonville, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 8, 2026, 9:36 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With BPH and LUTS

NCT01589263
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Track Symptoms
Interventions
onaBoNT-A + placebo, Tamsulosin + placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 8, 2026, 9:36 PM EDT
Recruiting Phase 2 Interventional

Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant

NCT05405387
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Leukemia
Interventions
Budesonide EC, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 8, 2026, 9:36 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis

NCT05213624
View directory record Official record
Conditions
Kidney Disease, Chronic
Interventions
BI 764198, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
20
States / cities
Huntsville, Alabama • San Francisco, California • South Gate, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 8, 2026, 9:36 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis

NCT04853368
View directory record Official record
Conditions
Cystic Fibrosis (CF)
Interventions
ABBV-576, Galicaftor, Placebo, Navocaftor, ABBV-119
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
22
States / cities
Mobile, Alabama • Los Angeles, California • Ventura, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 8, 2026, 9:36 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

NCT03738215
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
65
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 8, 2026, 9:36 PM EDT
Completed Phase 2 Interventional Results available

12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin

NCT02647320
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sitagliptin 100 mg, DS-8500a 25mg, Placebo Tablet, Placebo Capsule
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 70 Years
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
48
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Tempe, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Oct 8, 2026, 9:36 PM EDT
Completed Phase 1 Interventional

Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients

NCT01290965
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Placebo, SCY-635
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
San Francisco, California • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 6, 2014 · Synced Oct 8, 2026, 9:36 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088

NCT06579300
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-1088, Placebo for ABBV-1088, Itraconazole (ITZ)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 8, 2026, 9:36 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder

NCT02841709
View directory record Official record
Conditions
Insomnia Disorder
Interventions
ACT-541468, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
65 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
5
States / cities
Brandon, Florida • Chicago, Illinois • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 8, 2026, 9:36 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder

NCT03569475
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Levomilnacipran ER, Fluoxetine, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
7 Years to 17 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
51
States / cities
Little Rock, Arkansas • Beverly Hills, California • Corona, California + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 8, 2026, 9:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Fish Oils on Inflammation and Insulin Resistance

NCT00579436
View directory record Official record
Conditions
Metabolic Syndrome, Insulin Resistance
Interventions
omega-3 fatty acid, placebo
Drug
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Oct 8, 2026, 9:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer

NCT01317199
View directory record Official record
Conditions
Prostate Cancer
Interventions
Muscadine Plus Grape Skin Extract, Low-dose MPX, High-dose MPX, Placebo oral capsule
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 8, 2026, 9:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Dose Ethnobridging PK Study in Healthy Subjects

NCT03750565
View directory record Official record
Conditions
Inflammatory Bowel Diseases, IBD
Interventions
TD-1473 - Dose A, TD-1473 - Dose B, TD-1473 - Dose C, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 8, 2026, 9:36 PM EDT
Completed Phase 3 Interventional Results available

PALISADE Follow-on Study (ARC004)

NCT02993107
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
47
States / cities
Tucson, Arizona • Little Rock, Arkansas • Mission Viejo, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Oct 8, 2026, 9:36 PM EDT